Pediatric Oncology I

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)
 
 
Steven G. DuBois, Meaghan Granger, Susan G. Groshen, et al.
 
The abstract concludes: 
The combination of vorinostat/MIBG had the highest response rate, with manageable toxicity. Vincristine and irinotecan do not improve the response rate to MIBG and are associated with increased toxicity. These data provide response rates for MIBG monotherapy in a contemporary patient population assessed with current response criteria. Clinical trial information: NCT02035137
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Keith Wheatley, Grace Holt, Cormac Owens, et al.
 
The abstract concludes: 
The BEACON results show that single agent T is suboptimal. Statistical uncertainty about an interaction between I and B means two further interpretations are possible: 1) IT and possibly BT are better than T; 2) IT and BT are not better than T, but I and B together (BIT) are better. Hence, a definitive conclusion on the best combination(s) to take forward is not currently possible and further randomized evaluation is needed. Clinical trial information: ISRCTN40708286.
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
10502 Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients ≥18 months with unfavorable histology and without MYCN amplification: A Children’s Oncology Group (COG) report.
 
Navin R. Pinto, Arlene Naranjo, Emily Hibbitts, et al.
 
The abstract concludes: 

High-risk therapy that included single myeloablative therapy led to an 81.6±5.3%5-year OS in patients ≥18 months with UH and MYCN–NA stage III neuroblastoma. Response to therapy is a powerful predictor of survival and the presence of chromosome 11q loss/LOH is also associated with inferior outcomes. These patients should continue to be treated on high-risk clinical trials.

U.S. National Institutes of Health Other Foundation

--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Cornelis Martinus van Tilburg, Elke Pfaff, Kristian W. Pajtler, et al.
 
The abstract concludes: 
Pediatric precision oncology in a real world, multi-national setting is feasible. The prioritization algorithm identifies subgroups benefitting from molecularly matched targeted treatment. Still, for the patients without a very high priority target further layers of molecular and functional data should be incorporated in future programs.
 
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Kelly C. Goldsmith, Kimberly Kayser, Susan G. Groshen, et al.
 
The abstract concludes: 
Inhibition of ALK-driven NB with lorlatinib occurs with manageable toxicity and objective anti-tumor activity. Prospective ctDNA allows for monitoring of disease and evolution of resistance. Clinical trial information: NCT03107988
 
PFIZER
--------------------------------------------------------------------------------------------------------------------------------------------------------
The abstract concludes: 
Substantial activity was observed with ceritinib at the RDE in pts with IMT, ALCL and heavily pretreated neuroblastoma. The toxicity profile of ceritinib in children was manageable and similar to that previously reported in adults. Clinical trial information: NCT01742286
Novartis Pharmaceuticals
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
The abstract concludes: 
In pediatric pts with pretreated BRAF V600-mutant LGG, D+T combination therapy demonstrated clinical activity, with 92% of pts having SD or better by independent review using the RANO criteria. Pyrexia and skin toxicity were the common AEs; majority of these were low-grade and manageable. Clinical trial information: NCT02124772
Novartis
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Michela Casanova, Francisco Bautista, Quentin Campbell Hewson, et al.
 
The abstract concludes: 
Regorafenib can be combined at its single agent RP2D of 82 mg/m2 with standard-dose vincristine/irinotecan (with appropriate dose modifications) in pediatric patients with refractory/relapsed solid tumors in a sequential dosing schedule. Clinical activity was observed in patients with sarcoma. Clinical trial information: NCT02085148
Bayer
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Pooja Hingorani, Mark D. Krailo, Allen Buxton, et al.
 
The abstract concludes: 
Dinutuximab toxicity in adolescent and young adult OS patients was similar to younger patients. While GD2 remains a relevant target in OS, combination of dinutuximab with GM-CSF did not meet the targeted successful DCR in patients with completely resected tumor. Other strategies for targeting GD2 or dinituximab combination therapy may still be warranted. Clinical trial information: NCT02484443
U.S. National Institutes of Health Other Foundation
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
DISCUSSANT
Theodore Willis Laetsch, MD | University of Texas Southwestern Medical Center and Children's Health
————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Poster Discussion Session
 
Poster Session